Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis

被引:84
作者
Chow, Ronald [1 ,2 ]
Hoskin, Peter [3 ,4 ]
Schild, Steven E. [5 ]
Raman, Srinivas [6 ]
Im, James [1 ]
Zhang, Daniel [1 ]
Chan, Stephanie [2 ]
Chiu, Nicholas [2 ]
Chiu, Leonard [2 ]
Lam, Henry [2 ]
Chow, Edward [2 ]
Lock, Michael [1 ]
机构
[1] Univ Western Ontario, London Hlth Sci Ctr, London Reg Canc Program, London, ON, Canada
[2] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[3] Mt Vernon Hosp, London, ON, Canada
[4] Univ Manchester, Manchester, Lancs, England
[5] Mayo Clin, Scottsdale, AZ USA
[6] British Columbia Canc Agcy, Vancouver Ctr, Vancouver, BC, Canada
关键词
Bone metastases; Palliative radiation; Randomized trials; Meta-analysis; Systematic review; RANDOMIZED-TRIAL; 8; GY; RADIOTHERAPY TRIALS; PAIN RELIEF; SCHEDULES; UPDATE;
D O I
10.1016/j.radonc.2019.06.037
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: There has been a long-standing debate regarding the efficacy of single fraction radiotherapy (SFRT) compared to multiple fraction radiotherapy (MFRT); many systematic reviews and meta-analyses have been conducted to resolve the debate and suggested SFRT is equally as effective as MFRT. Given the adequate amalgamated sample size that exists, it is difficult to appreciate the need for further RCTs. The aim of this paper was to conduct a cumulative meta-analysis to determine whether further trials will be of value to the meta-conclusion. This paper also assessed publication quality. Methods: A total of 29 studies were used in our meta-analysis. Comprehensive Meta-Analysis (Version 3) by Biostat was used to conduct a cumulative meta-analysis. The Cochrane Risk of Bias assessment tool was employed to assess study quality of the included RCTs. Funnel plots were generated using Review Manager (RevMan 5.3) by Cochrane IMS, to visually assess for publication bias. Results: All but one endpoint, overall response rates in assessable patients, maintained the same metaconclusion over publication time; published studies did not change the amalgamated scientific conclusion of existing literature. Additional studies have simply confirmed pre-existing conclusions and refined the point estimate of the efficacy estimate. The majority of included studies have low risk of bias. Conclusion: In conclusion, the meta-conclusion has remained consistent over time - SFRT is equally as efficacious as MFRT. Recent studies have had little impact on the overall conclusion, and given the vast amount of resources to execute a randomized trial, future resources should not be used to repeat these studies, and can be better allocated to test other hypotheses. (C) 2019 Elsevier B.V. All rights reserved.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 40 条
  • [1] Altundag MB, 2002, TURK J HEMATOL ONCOL, V12, P16
  • [2] [Anonymous], PRACT RAD ONCOL
  • [3] [Anonymous], ONCOLOGY 10 THINGS P
  • [4] [Anonymous], 5 THINGS PHYS PAT SH
  • [5] [Anonymous], J CLIN ONCOL
  • [6] [Anonymous], B ALEX FAC MED
  • [7] [Anonymous], 2008, CURR ONCOL, DOI 10.3747/co.v15i3.203
  • [8] Anter AH, 2015, Forum Clin Oncol, V6, P8
  • [9] Ashton A, 1999, RADIOTHER ONCOL, V52, P111
  • [10] Badzio A., 2003, J ONCOL, V53, P261